


TGX-155

Cat. No.:	HY-105666
CAS No.:	351071-90-4
Molecular Formula:	C ₂₀ H ₁₉ FN ₂ O ₃
Molecular Weight:	354.37
Target:	PI3K
Pathway:	PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TGX-155 (AZ12649385) is a selective inhibitor of PI3K β . TGX-155 has potential applications in antithrombotic therapy ^{[1][2][3]} .
IC ₅₀ & Target	PI3K β
In Vivo	TGX-155 (1.5 mg/kg and 2.5 mg/kg; i.v.; single dose) significantly improves the cyclic flow reductions (CFRs) in rabbit carotid artery injury in a time-dependent and dose-dependent manner ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Verheijen J C, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs[J]. *Drugs Future*, 2007, 32(6): 537-547.
- [2]. Nylander S, et al. Human target validation of phosphoinositide 3-kinase (PI3K) β : effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K β inhibitor. *J Thromb Haemost*. 2012 Oct;10(10):2127-36.
- [3]. Sturgeon SA, et al. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. *J Pharmacol Toxicol Methods*. 2006 Jan-Feb;53(1):20-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA